{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The dose of vorinostat in mg/sqm/day to be administered with combination chemotherapy and radiation therapy","groups":[{"description":"Arm 1, Phase 1 participants received vorinostat at 180 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks).\n\nArm 2, Phase 1 participants received a higher dose of vorinostat at 230 mg/m\\^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks).","id":"OG000","title":"All Phase 1 Study Participants"}],"paramType":"NUMBER","populationDescription":"All patients enrolled on arm 1 and 2 who received at least 85% of the planned doses of radiation therapy and chemotherapy in the chemoradiotherapy portion of the study or who experienced DLT after after receiving at least one dose of chemoradio therapy and completing 7 weeks fo follow-up.","reportingStatus":"POSTED","timeFrame":"Planned 7 weeks during chemoradiotherapy","title":"Maximum Tolerated Dose (MTD) of Vorinostat","type":"PRIMARY","unitOfMeasure":"mg/m^2"}